Eimear Mylod

Jul 25, 2024 | cell.com | Eimear Mylod |Elise Jenkins |Gearóid Conlon

Highlights•Tumor-treating fields (TTFs) do not affect natural killer (NK) cell viability•TTF exposure increased NK cell cytotoxic degranulation against GBM cells•TTFs had no effect on NK cell cytokine productionSummaryTumor-treating fields (TTFs) are a non-invasive treatment for glioblastoma (GBM) that applies low-intensity, intermediate-frequency, alternating electric fields. Given a 5-year survival of less than 7% for GBM patients, multi-modal treatments are required to improve survival.